Novel anti-cd5 chimeric antigen receptors and uses thereof
By designing antibodies and chimeric antigen receptors (CARs) that specifically bind to CD5, the self-destructive problem in CAR-T cell therapy for T-cell tumors was solved, improving the survival rate of immune cells and the tumor-killing ability, thus achieving effective treatment of CD5 cancer cells.
Patent Information
- Application Number
- CN202480090860.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-04-18
- Filing Date
- 2024-07-31
- Publication Date
- 2026-11-10
AI Technical Summary
Existing CAR-T cell therapy agents exhibit cannibalism when treating T-cell tumors, leading to problems such as low cell survival rate, low proliferation capacity, and cell exhaustion. Furthermore, their therapeutic effect on CD5-expressing cancer cells is not significant.
An antibody or its antigen-binding fragment that specifically binds to CD5 was designed, and a chimeric antigen receptor (CAR) containing an extracellular binding domain, a transmembrane domain, and an intracellular signal transduction domain was constructed and expressed on the surface of immune cells. The intracellular signal transduction domain was optimized to reduce cannibalism.
It achieved specific recognition and killing of CD5-expressing cancer cells, reduced reactivity to normal cells, improved the survival rate and proliferation capacity of immune cells, and enhanced the ability to kill tumor cells in vitro and in vivo.
Smart Images

Figure CN123076609A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to a novel anti-CD5 chimeric antigen receptor and its uses, and more specifically, to an antibody that specifically binds to CD5 or an antigen-binding fragment thereof, a chimeric antigen receptor comprising said antibody or an antigen-binding fragment thereof, and an immune cell expressing said chimeric antigen receptor. Background Technology
[0002] The global market for anti-cancer drugs has grown at an average annual rate of 10-13% over the past decade, and is projected to reach a total of US$200 billion by 2022. As of 2020, one in five men and one in six women worldwide will develop cancer at least once in their lifetime, and one in eight men and one in eleven women will die from cancer. The incidence and mortality rates of cancer continue to rise.
[0003] The global anti-cancer drug market is undergoing a paradigm shift, moving from first-generation chemotherapy drugs to second-generation targeted anti-cancer drugs, and then to third-generation tumor immunotherapy drugs. Currently, treatment methods that merely aimed to shrink or inhibit cancer are gradually being abandoned, and research is actively underway on targeted anti-cancer therapies that selectively attack cancer cells without damaging normally rapidly dividing cells. The development of these targeted anti-cancer therapies involves two phases: screening for receptors specifically expressed in cancer cells that can selectively target them, and developing targeted compounds that bind to these receptors.
[0004] Among them, cell therapy that utilizes immune cells, such as enhancing immune cells or genetically engineering them and then re-injecting them into the patient's body, is receiving increasing attention. For example, research is underway on technologies such as tumor infiltrating lymphocytes (TIL), chimeric antigen receptors (CAR), and T-cell receptors (TCR).
[0005] In particular, research on CAR-T cells, which are T cells implanted with chimeric antigen receptors (CARs) designed to confer antigen specificity, has been actively pursued since CD19-targeting CAR-T cells were approved by the FDA as an anticancer drug in 2017. However, most CAR-T cells have only shown efficacy in vitro, failing to demonstrate significant therapeutic effects in vivo.
[0006] On the other hand, while CAR-T cells are effective against tumors, they also have the side effect of non-specifically attacking healthy tissues in some cases. CD5 is a differentiation cluster expressed in T cells and B cells, mainly found in bone marrow or lymphoid tissues, and is overexpressed in T cells compared to B cells, thus it is mainly used as a marker for T cells.
[0007] In addition, most lymphomas originating from T cells, such as peripheral T-cell lymphoma, anaplastic large cell lymphoma, and extranodal NK / T-cell lymphoma, express CD5. Abnormal B cells also express CD5, and some lymphomas originating from B cells, such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma, also express CD5.
[0008] However, for CAR-T therapy for T-cell tumors, since the cells to which the CAR gene is introduced are also T cells, fratricide, a phenomenon where CAR-T cells kill each other, can occur during the culture process when transducing CARs that target T cells. This phenomenon leads to adverse indicators such as low cell survival rate, low proliferation capacity, release of cytokines during culture, and cell exhaustion due to continuous stimulation.
[0009] Therefore, it is necessary to study and develop immune cells that can improve the aforementioned problems of anti-CD5 CAR-T cells while maintaining anti-cancer activity against CD5-expressing cancer cells. Summary of the Invention
[0010] Technical issues
[0011] The technical problem to be solved by the present invention is to provide an antibody or antigen-binding fragment that specifically binds to CD5.
[0012] Furthermore, the technical problem to be solved by the present invention is to provide an anti-CD5 chimeric antigen receptor comprising the antibody or its antigen-binding fragment.
[0013] Furthermore, the technical problem to be solved by the present invention is to provide a nucleic acid molecule encoding the chimeric antigen receptor.
[0014] Furthermore, the technical problem to be solved by the present invention is to provide an expression vector containing the nucleic acid molecule.
[0015] Furthermore, the technical problem to be solved by the present invention is to provide an immune cell that expresses the chimeric antigen receptor.
[0016] Furthermore, the technical problem to be solved by the present invention is to provide a pharmaceutical composition comprising the immune cells for the prevention or treatment of cancer.
[0017] The technical problems to be solved by the present invention are not limited to the above-mentioned technical problems. Based on the following description, those skilled in the art will be able to clearly understand other technical problems not mentioned.
[0018] Problem-solving methods
[0019] To address the aforementioned technical problems, one embodiment of the present invention provides an antibody or antigen-binding fragment thereof that specifically binds to CD5, comprising:
[0020] The light chain variable region includes: a light chain CDR1 having any of the amino acid sequences of sequence numbers 1, 10, 19, and 28; a light chain CDR2 having any of the amino acid sequences of sequence numbers 2, 11, 20, and 29; and a light chain CDR3 having any of the amino acid sequences of sequence numbers 3, 12, 21, and 30; and
[0021] The heavy chain variable region includes: a heavy chain CDR1 having any of the amino acid sequences of sequence numbers 4, 13, 22 and 31; a heavy chain CDR2 having any of the amino acid sequences of sequence numbers 5, 14, 23 and 32; and a heavy chain CDR3 having any of the amino acid sequences of sequence numbers 6, 15, 24 and 33.
[0022] In one embodiment of the present invention, the antibody or its antigen-binding fragment may comprise any amino acid sequence from sequence numbers 9, 18, 27, and 36.
[0023] In one embodiment of the present invention, the antibody or its antigen-binding fragment may bind to the proximal extracellular membrane domain of CD5.
[0024] In one embodiment of the present invention, the proximal extracellular membrane domain of CD5 may contain the amino acid sequence of sequence number 56.
[0025] In one embodiment of the present invention, the antibody or its antigen-binding fragment may be scFv, Fab fragment, F(ab') fragment, F(ab')2 fragment or Fv fragment.
[0026] To address the aforementioned technical problems, another embodiment of the present invention provides an anti-CD5 chimeric antigen receptor (CAR), comprising:
[0027] An extracellular binding domain, wherein the extracellular binding domain comprises the antibody or an antigen-binding fragment thereof;
[0028] Transmembrane domains; and
[0029] Intracellular signal transduction domain.
[0030] In one embodiment of the present invention, the intracellular signal transduction domain may be derived from at least one of the following: CD3 zeta, FcγR, ICOS (CD278), 4-1BB (CD137), OX40 (CD134), CD27, CD28, IL-2Rβ, IL-15R-α, CD40, MyD88, DAP10, DAP12, MHC Class I molecules, TNF receptor protein, immunoglobulin-like protein, cytokine receptor, integrin, SLAM protein, activated NK cell receptor, BTLA, Toll ligand receptor, CD2, CD7, CD30, CD40, CDS, ICAM-1, B7-H3, GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD19, CD4, CD8α, CD8β, IL2Rγ, IL7Rα, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD 11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, ITGB7, NKG2D, NKG2C, TNFR2, TRANCE / RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG / Cbp, CD19a and CD83 specific ligands.
[0031] In one embodiment of the present invention, the transmembrane domain may be derived from any of the following: T cell receptor (TCR) α chain, TCR β chain, CD3ζ, CD3ε, CD28, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154, and CD278.
[0032] In one embodiment of the present invention, the chimeric antigen receptor may further include a hinge domain, wherein the extracellular binding domain is connected to the transmembrane domain through the hinge domain, and the hinge domain may be derived from any one of CD8, FcγRIIIα and IgG1.
[0033] In one embodiment of the present invention, the chimeric antigen receptor may comprise any amino acid sequence from sequence numbers 51 to 54.
[0034] To address the aforementioned technical problems, another embodiment of the present invention provides a nucleic acid molecule encoding the chimeric antigen receptor.
[0035] To address the aforementioned technical problems, another embodiment of the present invention provides an expression vector containing the nucleic acid molecule.
[0036] To address the aforementioned technical problems, another embodiment of the present invention provides an immune cell expressing the chimeric antigen receptor.
[0037] In one embodiment of the present invention, the immune cell may be at least one selected from T cells, natural killer T cells, dendritic cells, cytotoxic dendritic cells, mast cells, natural killer cells, macrophages and their precursor cells.
[0038] To address the aforementioned technical problems, another embodiment of the present invention provides a pharmaceutical composition comprising the immune cells for the prevention or treatment of cancer.
[0039] The effects of the invention
[0040] This invention relates to a novel anti-CD5 chimeric antigen receptor and its uses. The chimeric antigen receptor of this invention can specifically bind to the proximal extracellular membrane domain of CD5, and immune cells expressing the chimeric antigen receptor exhibit reduced responsiveness to normal cells expressing CD5, thus it can be used as an effective therapeutic agent for various CD5-mediated cancers.
[0041] The effects of the present invention are not limited to those described above, but should be understood to include all effects that can be derived from the technical solutions described in the present invention specification or claims. Attached Figure Description
[0042] Figure 1 This graph shows the results of determining whether the scFv targeting CD5 obtained in this invention binds to the CD5 protein.
[0043] Figure 2This is a schematic diagram illustrating the structure of the chimeric antigen receptor (CAR) used in this invention, showing the structure of the CAR containing H65 as a positive control scFv and A2 and C7 scFv obtained in this invention.
[0044] Figure 3 This is a graph showing the results of transducing CD5 CAR into CD5-negative cell lines and measuring their binding ability to recombinant CD5 protein.
[0045] Figure 4 This diagram shows the structure of the mutant CD5 prepared to confirm the binding site, as well as the results of confirming the binding site of the positive control and A2 and C7 scFv to the CD5 protein.
[0046] Figure 5 This is a diagram showing the results of measuring CAR expression patterns in CD5 CAR transduced cells.
[0047] Figure 6 This is a graph showing the results of measuring the cell viability and proliferation capacity of CD5 CAR transduced cells.
[0048] Figure 7 This graph shows the results of measuring the secretion of IFN-γ and TNF-α in CD5 CAR transduced cells during culture.
[0049] Figure 8 This is a graph showing the results of cell phenotype determination based on the expression patterns of various surface markers in CD5 CAR transduced cells.
[0050] Figure 9 This is a graph showing the results of measuring the in vitro tumor cell killing ability of CD5 CAR transduced cells.
[0051] Figure 10 shows the results of measuring the in vivo tumor cell killing ability of CD5 CAR transduced cells.
[0052] Figure 11 This is a graph showing the results of determining whether the scFv targeting the CD5 membrane-proximal domain obtained in this invention binds to the CD5 protein.
[0053] Figure 12 This is a schematic diagram illustrating the configuration of the chimeric antigen receptor (CAR) used in this invention, showing the configuration of CARs using scFv targeting the distal CD5 membrane domain and scFv targeting the proximal CD5 membrane domain, wherein the scFv targeting the distal CD5 membrane domain includes H65 as a positive control scFv.
[0054] Figure 13 This is a graph showing the results of transducing CD5 CAR into CD5-negative cell lines and measuring their binding ability to recombinant CD5 protein.
[0055] Figure 14 This diagram shows the results of confirming the binding sites of the positive control and the scFv obtained in this invention to the CD5 protein.
[0056] Figure 15 shows the results of measuring CAR expression patterns in CAR transduced cells targeting the proximal domain of the CD5 membrane.
[0057] Figure 16 This is a graph showing the results of measuring the cell viability and proliferation capacity of CAR transduced cells targeting the proximal domain of the CD5 membrane.
[0058] Figure 17 This is a diagram showing the results of cell phenotype determination based on the expression patterns of various surface markers in CAR transduced cells targeting the proximal domain of the CD5 membrane.
[0059] Figure 18 This is a graph showing the results of measuring the in vitro tumor cell killing ability of CAR transduced cells targeting the proximal domain of the CD5 membrane.
[0060] Figure 19 This is a graph representing the in vivo tumor cell killing ability of CAR transduced cells targeting the proximal domain of the CD5 membrane. Detailed Implementation
[0061] The present invention will now be described in detail.
[0062] This invention relates to antibodies that specifically bind to CD5 or antigen-binding fragments thereof.
[0063] As used in this invention, the term "antibody" refers to an immunoglobulin molecule that specifically binds to an epitope of an antigen and is reactive. The antibody may include monoclonal antibodies, polyclonal antibodies, antibodies with a full-length chain structure (full-length antibody), functional fragments with at least antigen-binding function (antigen-binding fragments), and recombinant antibodies.
[0064] The monoclonal antibody refers to an antibody molecule with a single molecular composition obtained from a substantially identical antibody population. Such a monoclonal antibody exhibits a single binding specificity and affinity for a specific epitope.
[0065] The full-length antibody has a structure comprising two full-length light chains and two full-length heavy chains, with each light chain linked to the heavy chain via disulfide bonds.
[0066] The antibody comprises a heavy chain (HC) and a light chain (LC) polypeptide, wherein the heavy chain and light chain may include variable regions and constant regions.
[0067] The constant region is the area that mediates the binding of the antibody to various types of cells in the immune system (such as T cells), host tissues containing components of the complement system, etc.
[0068] For antibodies of the same type derived from the same species, the constant region performs the same function regardless of the type of antigen, and the amino acid sequence constituting the constant region is the same or has a high degree of similarity among different antibodies.
[0069] The constant region can be divided into the heavy chain constant region (CH) and the light chain constant region (CL).
[0070] The variable region is the region in the antibody that is specific to the antigen, and can be divided into the heavy chain variable region (VH) and the light chain variable region (VL).
[0071] The variable region may include 3 CDRs (complementary-determining regions) and 4 FRs (framework regions).
[0072] The CDR can be a circular region involved in antigen recognition, and the specificity for the antigen can be determined based on the amino acid sequence of the CDR.
[0073] The CDRs can be referred to as CDR1, CDR2, and CDR3 in sequence, and depending on whether the CDRs are heavy chain polypeptides or light chain polypeptides, they can be referred to as CDR-H1, CDR-H2, and CDR-H3 in the case of heavy chain variable regions, and as CDR-L1, CDR-L2, and CDR-L3 in the case of light chain variable regions.
[0074] Similarly, for FR, in the case of heavy chain variable regions, they can be referred to as FR-H1, FR-H2, FR-H3 and FR-H4, and in the case of light chain variable regions, they can be referred to as FR-L1, FR-L2, FR-L3 and FR-L4.
[0075] The antigen-binding fragment of the present invention refers to any fragment of the antibody of the present invention that maintains the antigen-binding function.
[0076] The antigen-binding fragment can be used interchangeably with terms such as "fragment" or "antibody fragment". For example, the antigen-binding fragment can be scFv, Fab fragment, F(ab') fragment, F(ab')2 fragment, or Fv fragment.
[0077] The scFv is a structure that connects VH and VL through a linker to form a continuous protein chain, and it is generally known to have a superior binding capacity to antigens compared to using VH or VL alone.
[0078] At this point, any connector used to connect VH and VL can be a connector commonly used in the art, and there are no particular restrictions.
[0079] The linker can be a peptide linker and can have a length of about 10 to 25 amino acids.
[0080] For example, the connector may contain hydrophilic amino acids such as glycine (G) and / or serine (S).
[0081] More specifically, the connector can be GGSSRSSSSGGGGSGGGG.
[0082] The antibody or antigen-binding fragment thereof of the present invention comprises:
[0083] The light chain variable region includes: a light chain CDR1 having any of the amino acid sequences of sequence numbers 1, 10, 19, and 28; a light chain CDR2 having any of the amino acid sequences of sequence numbers 2, 11, 20, and 29; and a light chain CDR3 having any of the amino acid sequences of sequence numbers 3, 12, 21, and 30; and
[0084] The heavy chain variable region includes: a heavy chain CDR1 having any of the amino acid sequences of sequence numbers 4, 13, 22 and 31; a heavy chain CDR2 having any of the amino acid sequences of sequence numbers 5, 14, 23 and 32; and a heavy chain CDR3 having any of the amino acid sequences of sequence numbers 6, 15, 24 and 33.
[0085] The light chain variable region may, for example, contain any of the amino acid sequences in sequence numbers 7, 16, 25, and 34.
[0086] The heavy chain variable region may, for example, contain any of the amino acid sequences in sequence numbers 8, 17, 26, and 35.
[0087] More specifically, the antibody or its antigen-binding fragment may contain any of the amino acid sequences in sequence numbers 9, 18, 27, and 36.
[0088] The antibody or its antigen-binding fragment can specifically bind to the proximal domain of the CD5 extracellular membrane. The proximal domain of the CD5 extracellular membrane may, for example, contain the amino acid sequence at sequence number 56.
[0089] The antibodies or antigen-binding fragments of the present invention may, for example, include heavy chain constant regions and / or light chain constant regions derived from human antibodies.
[0090] The heavy chain constant region and / or light chain constant region of the human-derived antibody may be used without limitation on their type or amino acid sequence, provided that it does not impair the ability of the antibody or its antigen-binding fragment to specifically bind to CD5.
[0091] The range of antibody or antigen-binding fragments of the present invention includes variants with conserved amino acid substitutions in the CDR region, and may include variants relative to the amino acid sequences listed above within the range capable of specifically recognizing CD5.
[0092] For example, in order to further improve antibody properties other than binding affinity, such as half-life, biocompatibility, and other biological properties, further changes can be made to the amino acid sequence of the antibody.
[0093] In view of variants having such biologically equivalent activity, the antibodies or nucleic acid molecules encoding them of the present invention should be interpreted as also including sequences that show substantial sequence identity with the recorded sequence.
[0094] The substantial sequence identity refers to a sequence that, when compared with any other sequence to achieve the greatest possible correspondence, and analyzed using algorithms commonly used in the art, shows at least 61% sequence identity, 70% sequence identity according to one specific example, 80% sequence identity according to another specific example, and 90% sequence identity according to yet another specific example.
[0095] This invention relates to anti-CD5 chimeric antigen receptors.
[0096] The chimeric antigen receptor of the present invention comprises: an extracellular binding domain containing the antibody or an antigen-binding fragment thereof; a transmembrane domain; and an intracellular signal transduction domain.
[0097] Regarding the antibody or its antigen-binding fragment, as described above.
[0098] The intracellular signal transduction domain is a portion of the immune cell designed to induce immune cell function (e.g., activation of cytotoxic or lytic factors against target cells bound to the chimeric antigen receptor and antigen, cytokine production, proliferation, and cytotoxic or lytic activity, or other cellular responses induced by said antigen binding), transmitting signals generated by the binding of the chimeric antigen receptor to the interior of the immune cell. The intracellular signal transduction domain may be part of a protein that transmits effector signals and instructs the cell to perform specific functions.
[0099] As the intracellular signal transduction domain, intracellular signal transduction domains previously used in the development of chimeric antigen receptors can be used. For example, the intracellular signal transduction domain can be derived from one or more of the following: CD3 zeta, FcγR, ICOS (CD278), 4-1BB (CD137), OX40 (CD134), CD27, CD28, IL-2Rβ, IL-15R-α, CD40, MyD88, DAP10, DAP12, MHC. Class I molecules, TNF receptor protein, immunoglobulin-like protein, cytokine receptor, integrin, SLAM protein, activated NK cell receptor, BTLA, Toll ligand receptor, CD2, CD7, CD30, CD40, CDS, ICAM-1, B7-H3, GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD19, CD4, CD8α, CD8β, IL2Rγ, IL7Rα, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD Specific ligands for 11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, ITGB7, NKG2D, NKG2C, TNFR2, TRANCE / RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG / Cbp, CD19a, and CD83 can be used. More specifically, CD3 zeta and 4-1BB co-stimulatory signal sequences can be used.
[0100] The transmembrane domain refers to a region that connects and fuses an extracellular domain and an intracellular signal transduction domain, anchoring the chimeric antigen receptor to the cytoplasmic membrane of immune cells. The transmembrane domain can be derived from natural, synthetic, semi-synthetic, or recombinant sources. For example, the transmembrane domain can be derived from any of the following sequences: T cell receptor (TCR) α chain, TCR β chain, CD3ζ, CD3ε, CD28, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154, and CD278. More specifically, a transmembrane domain sequence derived from CD8 can be used.
[0101] The chimeric antigen receptor further includes a hinge domain, the extracellular binding domain being connected to the transmembrane domain via the hinge domain, and the hinge domain may be derived, for example, from any one selected from CD8, FcγRIIIα, and IgG1. More specifically, it may contain a hinge sequence derived from CD8.
[0102] The chimeric antigen receptor may further include a signal peptide for domain exposure. The signal peptide may be a signal peptide of any secreted protein or transmembrane protein, which directs the chimeric antigen receptor to transport to the cell membrane or cell surface and provides correct localization. The signal peptide may be derived from any of CD8, IgG1 heavy chain, Ig kappa light chain, and GMCSF. More specifically, it may be a CD8-derived signal peptide.
[0103] This invention relates to nucleic acid molecules encoding the chimeric antigen receptor.
[0104] The term "nucleic acid molecule" as used in this invention has a broad meaning that includes DNA (gDNA and cDNA) and RNA molecules, and that nucleotides, which are the basic building blocks of nucleic acid molecules, include not only natural nucleotides but also analogues with modified sugar or base portions (Scheit, Nucleotide Analogs, John Wiley, New York (1980); Uhlman and Peyman, Chemical Reviews, (1990) 90:543-584). The sequences of nucleic acid molecules encoding the heavy and light chain variable regions of this invention can be modified. Such modifications include the addition, deletion, non-conservative substitution, or conserved substitution of nucleotides.
[0105] This invention relates to expression vectors containing the nucleic acid molecules.
[0106] The expression vector may contain an expression regulatory sequence operatively linked to the nucleic acid.
[0107] As used in this invention, the term "vector" refers to a nucleic acid molecule capable of carrying other nucleic acids linked to it. For example, the vector can be a plasmid, i.e., a circular double-stranded DNA fragment capable of linking an additional DNA fragment. Furthermore, the vector can be a viral vector, i.e., a vector capable of linking an additional DNA fragment to a viral genome. The vector can autonomously replicate within a host cell in which it is introduced. For example, it can be a bacterial vector with a bacterial origin of replication or an episomal mammalian vector. Furthermore, the vector (e.g., a non-episomal mammalian vector) can integrate into the host cell's genome upon introduction, thereby replicating along with the host genome. Moreover, any vector can enable the expression of genes operatively linked to it.
[0108] The term "expression regulatory sequence" as used in this invention refers to a polynucleotide sequence linked to a coding sequence and essential for the expression and processing of said coding sequence. The expression regulatory sequence includes appropriate transcription initiation sequences, termination sequences, promoters, enhancer sequences, effective RNA processing signals such as splicing and polyadenylation signals, sequences stabilizing cytoplasmic mRNA, sequences that improve translation efficiency (i.e., Kozak concordant sequences), and sequences that enhance protein stability, and, when necessary, sequences that promote protein secretion. The nature of such expression regulatory sequences varies depending on the host organism. For prokaryotes, such expression regulatory sequences typically include a promoter, a ribosome binding site, and a transcription termination sequence; for eukaryotes, such expression regulatory sequences include a promoter and a transcription termination sequence. In this invention, the expression regulatory sequence includes at least all components essential for the expression and processing process, and may also include additional components that are advantageous, such as leader sequences and fusion chaperone sequences.
[0109] This invention relates to immune cells that express the chimeric antigen receptor.
[0110] Regarding the chimeric antigen receptor, as previously stated.
[0111] The immune cells express the chimeric antigen receptor on their surface. Chimeric antigen receptor expression on the surface of immune cells refers to any immune cell manipulated by adding or modifying nucleic acids encoding the chimeric antigen receptor.
[0112] Therefore, in order to express the chimeric antigen receptor on the surface of immune cells as described above, the polynucleotide encoding the chimeric antigen receptor or an expression vector containing the polynucleotide can be transfected or transduced into the immune cells. The transfection can be performed by various methods known in the art, such as calcium phosphate-DNA coprecipitation, DEAE-dextran-mediated transfection, polybrene-mediated transfection, electroporation, microinjection, liposome fusion, liposome transfection reagents, and protoplast fusion. Furthermore, transfection refers to the delivery of a gene into a cell using a virus or viral vector particles through infection. In this specification, transfection and transduction can be used interchangeably, but it is preferred to interpret both broadly as the transformation of delivering a foreign gene to a host cell, and cells that have introduced a foreign gene through transfection or transduction are referred to as transformed organisms.
[0113] The immune cells can be used without restriction, as long as they are cells capable of producing the desired therapeutic effect through induced immunity. They can be obtained from peripheral blood, umbilical cord blood, bone marrow, tumor-infiltrating lymphocytes, lymph node tissue, or thymus tissue, or by differentiating placental cells, embryonic stem cells, induced pluripotent stem cells, or hematopoietic stem cells. Furthermore, the immune cells can be obtained from humans, monkeys, chimpanzees, dogs, cats, mice, rats, and their transgenic species, as well as established cell lines.
[0114] Regarding the method for obtaining the immune cells, any method known in the art can be used, and the immune cells can be autologous, allogeneic, or xenogeneic. "Autologous" means all cells derived from the same individual from which the cells will subsequently be reintroduced; "allogeneic" means all cells derived from other animals belonging to the same species as the individual from which the cells are introduced; "xenogeneic" means cells derived from animals of different species.
[0115] The immune cells may be, for example, at least one selected from T cells, natural killer T cells, dendritic cells, cytotoxic dendritic cells, mast cells, natural killer cells, macrophages and their precursor cells.
[0116] The immune cells expressed by chimeric antigen receptors containing antibodies or antigen-binding fragments thereof that specifically bind to the proximal domain of the CD5 cell membrane have the advantage of exhibiting lower fratricide compared to immune cells expressing chimeric antigen receptors containing antibodies or antigen-binding fragments thereof that bind to the proximal domain of the CD5 cell membrane.
[0117] This invention relates to pharmaceutical compositions comprising the aforementioned immune cells for the prevention or treatment of cancer.
[0118] Regarding the immune cells, as previously stated.
[0119] The term cancer and "tumor" are used interchangeably, and generally refer to or indicate a physiological state in mammals characterized by uncontrolled cell growth / proliferation.
[0120] The cancer may include all cancers or cancer types that can be treated with the pharmaceutical compositions of the present invention, for example, peripheral T-cell lymphoma, angioimmunoblastic T-cell lymphoma, follicular T-cell lymphoma, anaplastic large-cell lymphoma, adult T-cell leukemia / lymphoma, hepatosplenic T-cell lymphoma, mycosis fungoides, Sézary syndrome, extranodal NK / T-cell lymphoma, primary cutaneous gamma / delta T-cell lymphoma, cutaneous T-cell lymphoma, and mantle cell lymphoma. T-cell lymphoma, T-cell acute lymphoblastic lymphoma, chronic lymphoblastic lymphoma, thymic carcinoma, non-Hodgkin lymphoma, diffuse large cell lymphoma, small lymphocytic lymphoma, or T-cell neoplasm.
[0121] The term "treatment" as used in this invention refers to the effect of improving or causing beneficial changes in symptoms caused by cancer.
[0122] The term “prevention” as used in this invention refers to the prevention of disease or disorder, or the onset, recurrence or spread of one or more symptoms caused by said disease / disorder, and may include prophylactic treatment for potential candidates.
[0123] The pharmaceutical compositions of the present invention further comprise a pharmaceutically acceptable carrier, which is a carrier commonly used in formulation, including but not limited to lactose, glucose, sucrose, sorbitol, mannitol, starch, gum arabic, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, water, syrup, methylcellulose, methylparaben, propylparaben, talc, magnesium stearate, and mineral oil.
[0124] In addition to the above-mentioned components, the pharmaceutical composition of the present invention may further include lubricants, humectants, sweeteners, flavoring agents, emulsifiers, suspending agents, preservatives, etc.
[0125] Appropriate pharmaceutically acceptable carriers and formulations are detailed in Remington's Pharmaceutical Sciences (19th ed., 1995).
[0126] The appropriate dosage of the pharmaceutical composition of the present invention can vary depending on factors such as formulation method, administration method, patient's age, weight, gender, severity of disease symptoms, diet, administration time, route of administration, excretion rate and response sensitivity. Generally, a skilled physician can easily determine and prescribe the dosage that is effective for the desired treatment.
[0127] On the other hand, the dosage of the pharmaceutical composition of the present invention is not limited thereto, and can be 0.01 to 2000 mg / kg (body weight) per day.
[0128] The pharmaceutical composition of the present invention can be administered orally or non-orally. In the case of non-oral administration, it can be administered by intravenous infusion, subcutaneous injection, intramuscular injection, intraperitoneal injection, transdermal administration, etc.
[0129] The route of administration of the pharmaceutical composition of the present invention is preferably determined according to the type of disease to which it is applicable.
[0130] The pharmaceutical compositions of the present invention can be formulated using pharmaceutically acceptable carriers and / or excipients in a manner readily practiced by those skilled in the art, thereby preparing them in unit dose form or in multi-dose containers.
[0131] At this time, the formulation may be in the form of a solution, suspension or emulsion in an oily or aqueous medium, or in the form of an extract, powder, granule, tablet or capsule, and may further contain a dispersant or stabilizer.
[0132] The present invention will be described in detail below through embodiments.
[0133] Experimental methods and results
[0134] 1. Screening and Characterization Results of Novel scFvs Targeting CD5
[0135] CD5 is a target cell surface protein used in CAR-T therapy agents for the treatment of T-cell tumors.
[0136] In constructing CAR-T therapeutic agents for treating T-cell tumors, two novel scFvs targeting CD5 and intended for use at the antigen-binding site of the CAR structure were screened using phage display to develop superior CAR structures.
[0137] To confirm whether the two screened scFvs actually bind to CD5, the scFv proteins were bound to CD5-positive Jurkat cell lines and CD5-negative NLAM-6 cell lines that continuously express CD5 on their cell surface, and flow cytometry was used to confirm whether binding occurred. Figure 1 ).
[0138] Compared with the NALM-6 cell line and isotype control used as negative controls, the two screened scFvs were confirmed to bind to the Jurkat cell line.
[0139] The structure of the CD5 CAR used in the CD5 CAR-T therapeutic agent of the present invention is shown in [illustration]. Figure 2 .
[0140] The CD5 CAR has the following structure: a CD8-derived signaling domain; an anti-CD5 scFv sequence (VL-linker-VH domain); a c-myc-derived myc-tag domain; a CD8-derived hinge domain; a CD8-derived transmembrane domain; a 4-1BB-derived intracellular signaling domain; a CD3z-derived intracellular signaling domain; and a stop codon TAA connected in sequence.
[0141] Based on the types of anti-CD5 scFv sequences, three CAR structures are shown in... Figure 2 H65 scFv was the positive control scFv.
[0142] To confirm the CD5 binding capacity of the screened scFvs, each CAR molecule composed of the screened scFvs was transduced into the K562 cell line, which is a CD5-negative cell line.
[0143] In K562 cell lines expressing various CAR molecules, the expression of CAR molecules was confirmed using myc-tag. Figure 3 a).
[0144] Recombinant human CD5 protein was incorporated into three prepared cell lines and an untransduced K562 cell line, and the degree of binding was analyzed by flow cytometry based on the amount of recombinant human CD5 protein treated. Figure 3 b).
[0145] It was confirmed that there was no difference in the binding ability of CAR molecules of different structures to CD5.
[0146] To confirm the CD5 binding site of the screened scFv, three mutant CD5 sequences were prepared.
[0147] In the three extracellular domains of the CD5 protein, mutant CD5 (DX23) with the farthest domain from the cell membrane, domain 1 (D1), mutant CD5 (DXX3) with the farthest extracellular domain 1 and extracellular intermediate domain 2 removed, and wild-type CD5 were prepared. Following each CD5 sequence were sequentially linked a P2A self-cleaving peptide sequence linked by glycine (G)-serine (S)-glycine (G); an eGFP sequence; and a stop codon TAA. Figure 4 a).
[0148] Three mutant CD5 sequences were transduced into the K562 cell line, which is a CD5-negative cell line, and the transduction efficiency was analyzed by flow cytometry. Figure 4 b).
[0149] The above Figure 2 The CD5 CAR molecule shown is transduced into T cells.
[0150] CD5 CAR-transduced T cells were combined with the above Figure 4 The cell line b was co-cultured at an E:T ratio of 1:1 for 48 hours, and the amount of INF-γ released into the culture medium during co-culture was determined by the cytometric bead array method.
[0151] The raw values were standardized based on the GFP expression levels of the cell lines used in each co-culture. Figure 4 c).
[0152] Positive controls H65CAR5 and A2CAR5 only responded to K562-CD5(WT) and released INF-γ, but did not respond to CD5 with the distal domain of the CD5 membrane removed.
[0153] Furthermore, C7CAR5 releases INF-γ even when only the proximal domain of the CD5 membrane is present.
[0154] Therefore, it was confirmed that the positive controls H65 and A2 scFv bind to the distal domain of the extracellular membrane, while C7 scFv binds to the proximal domain of the extracellular membrane.
[0155] 2. Preparation and characterization of CD5-targeting CAR-T cells
[0156] CD4-positive or CD8-positive T cells were isolated and purified from peripheral blood mononuclear cells (PBMCs) of healthy donors. The purified T cells were named "TC".
[0157] Frozen TC cells were thawed, and T cell activation was induced for 48 hours using TransAct cells coated with CD3 and CD28 antibodies. The activated T cells were named "AT".
[0158] Lentiviral vectors for transducing the CD5CAR gene were processed in AT and cultured for 24 hours to transduce the CD5CAR gene.
[0159] The transduced T cells were harvested and cultured in CAR-T medium for 10 days. The cultured T cells were named "CT".
[0160] Mock cells without CAR gene transduction, H65CAR5 cells transduced with H65 CAR, A2CAR5 cells transduced with A2 CAR, and C7CAR5 cells transduced with C7 CAR were harvested, and the expression of CAR molecules was confirmed using myc-tag. Figure 5 ).
[0161] H65CAR5 and A2CAR5 showed similar CAR molecule positivity rates, while C7CAR5 showed a statistically significantly lower CAR molecule positivity rate (*p<0.05, **p<0.01, ***<0.001, ns: no significance).
[0162] To determine the extent of cannibalism, cell viability was measured at the end of the culture. Figure 6 a).
[0163] H65CAR5 and A2CAR5 showed similar cell viability, while C7CAR5 showed statistically significantly higher cell viability (*p<0.05, **p<0.01, ***<0.001, ns: no significance).
[0164] In addition, the proliferation capacity of CD5 CAR-transduced T cells was measured.
[0165] The proliferation rate of CD5 CAR-transduced T cells at 7 days of culture was confirmed by measuring the number of CD5 CAR-transduced T cells after transduction and further culture for 3 days, and the number of CD5 CAR-transduced T cells after further culture for 10 days. Figure 6 b).
[0166] H65CAR5 and A2CAR5 showed similar cell proliferation rates, while C7CAR5 showed a statistically significantly higher cell proliferation rate (*p<0.05, **p<0.01, ***<0.001, ns: no significance).
[0167] This confirms that the self-destructive level of C7CAR5 is low in CD5CAR-transduced T cells.
[0168] To determine the extent of cannibalism, the concentration of cytokines released into the culture medium during the culture process was measured. Figure 7 ).
[0169] During the culture process, a portion of the culture supernatant was recovered and stored in an ultra-low temperature freezer at -80°C.
[0170] After all culture steps were completed, the preserved culture supernatant was thawed, and the concentrations of INF-γ and TNF-α cytokines were measured using a cell counting bead array.
[0171] It was confirmed that, after day 6 of further culture, both cytokines were released from C7CAR5 at statistically significantly low levels (*p<0.05, **p<0.01, ***<0.001, ns: no significance).
[0172] This confirms that the self-destructive level of C7CAR5 is low in CD5CAR-transduced T cells.
[0173] To determine the extent of cannibalism, the levels of cell surface markers and cell depletion transcription factors at the end of culture were determined.
[0174] To confirm the persistent stimulation caused by cannibalism, flow cytometry was used to confirm the cell surface expression of CD69 protein, one of the markers of cell activation. Figure 8 a).
[0175] Statistically low levels of cell activation were confirmed in C7CAR5.
[0176] Furthermore, the increased levels of immune checkpoint receptors induced by continuous stimulation were confirmed. Figure 8 b).
[0177] The three immune checkpoint receptors observed, PD1, TIGIT, and LAG3, all showed statistically significantly low expression in C7CAR5.
[0178] Furthermore, intracellular staining flow cytometry (FACS) confirmed the levels of cell exhaustion transcription factors induced by continuous stimulation. Figure 8 c).
[0179] The levels of TOX transcription factor were confirmed to be statistically significantly lower in C7CAR5 (*p<0.05, **p<0.01, ***<0.001, ns: no significance).
[0180] This confirms that the self-destructive level of C7CAR5 is low in CD5CAR-transduced T cells.
[0181] 3. Analysis of the tumor cell killing ability of CD5 CAR-transduced T cells
[0182] 3-1) Analysis of the in vitro tumor cell killing ability of CD5 CAR-transduced T cells
[0183] CD5 CAR-transduced T cells were recovered and centrifuged at 600 xg for 3 minutes at room temperature.
[0184] Remove the supernatant, resuspend the cells in the test culture medium, and then determine the cell count.
[0185] Using the detection medium, the cell suspension was diluted and prepared to 3 x 10³ cells / 100 μL, based on CAR-positive cells.
[0186] Add target cell lines expressing GFP fluorescence to 96-well plates to achieve a density of 1 x 10⁶ cells / well. 4 cells / well (1x10) 5 (cells / mL, 100 μL).
[0187] Add 100 μL of CD5 CAR-transduced T cells to each well to make the ratio of E (CD5 CAR-transduced T cells):T (CD5 positive (Jurkat) or negative (NALM-6) target cell lines) 0.3:1.
[0188] As a negative control, a target-only group was also prepared by replacing the CD5 CAR transduced T cells with 100 μL of detection medium.
[0189] The total amount of GFP fluorescence released from each well was used to calculate the amount of target cell line by utilizing the phenomenon that the GFP fluorescence of the killed target cell line disappeared.
[0190] GFP fluorescence levels were measured using the IncuCyte real-time cell analysis system and standardized according to the following formula.
[0191] (Total GFP fluorescence intensity per well at each measurement time point / Total GFP fluorescence intensity per well at the first measurement time point) * 100 Figure 9 ).
[0192] The tumor-killing ability of CD5 CAR-transduced T cells against the Jurkat cell line, which is a CD5-positive cell line, was observed.
[0193] 3-2) In vivo tumor cell killing ability analysis of CD5 CAR transduced T cells
[0194] As laboratory animals, NOD.Cg-Prkdc was used with specific pathogen-free (SPF) cytokine. scid IL2γg tm1Sug / JicKoat (hereinafter referred to as NOG) mice (prepared by KOATECH Co., Ltd.).
[0195] Jurkat cells expressing firefly luciferase, used for mouse tumor transplantation, were prepared by thawing frozen cell lines and passaged every 3-4 days. All cancer cells were recovered and centrifuged on the day the tumors were transplanted into mice.
[0196] Remove the supernatant, resuspend the cells in cell line culture medium, and then determine the cell count.
[0197] Centrifuge again and remove the supernatant, then prepare a solution with a concentration of 5 x 10⁻⁶ using D-PBS. 6 Cell suspension of cells / mL.
[0198] The prepared cell suspension was injected into the tail vein at a rate of 0.2 mL per mouse in each experimental group, at a concentration of 1 x 10⁻⁶. 6 Transplanted cancer cells / head
[0199] Seven days after cancer cell transplantation, mice weighing 20-25 g were given 200 μL of D-fluorescein at a concentration of 15 mg / ml via intraperitoneal administration, followed by inhalation anesthesia with 2% isoflurane.
[0200] Small animal in vivo imaging (Perkin Elmer, IVISSpectrum Series) was performed 10–15 minutes after administration of D-fluorescein to confirm that cancer cells had been transplanted.
[0201] Eight days after cancer cell transplantation, the cultured CD5 CAR transduced T cells were recovered and centrifuged at 600 xg for 3 minutes at room temperature.
[0202] Remove the supernatant, resuspend the cells in the test culture medium, and then determine the cell count.
[0203] Centrifuge again and remove the supernatant. Using D-PBS, prepare a solution with a concentration of 5 x 10⁻⁶ cells based on CD5 CAR-positive T cells. 6 Cell suspension of cells / mL.
[0204] The prepared cell suspension was injected into the tail vein at a rate of 0.2 mL per mouse in each experimental group, at a concentration of 1 x 10⁻⁶. 6 Transplantation of CD5 CAR-transduced T cells / head.
[0205] Subsequently, for all animals, small animal in vivo imaging and image taking were performed 1-2 times per week during the experiment to track and observe the amount of cancer cells.
[0206] In addition, observe whether all animals die and evaluate the survival rate (Figure 10).
[0207] Small animal in vivo imaging results showed that C7CAR5 exhibited sustained anti-cancer efficacy compared to other groups. Figure 10a ).
[0208] In the in vivo imaging results of small animals represented by individual mice, C7CAR5 also showed sustained anti-cancer efficacy compared to other groups. Figure 10b ).
[0209] The results confirming survival rates showed that C7CAR5 survived longer than the other groups. Figure 10c ).
[0210] This confirms that C7CAR5 has a high in vivo tumor cell killing ability in CD5 CAR transduced T cells.
[0211] 4. Screening and Characterization Results of Novel scFvs Targeting the Proximal Domain of the CD5 Membrane
[0212] As mentioned above, compared with H65CAR5 and A2CAR5 using existing positive controls H65 scFv, C7CAR5 exhibits lower self-killing ability and superior tumor cell killing ability in vivo.
[0213] Furthermore, it was confirmed that, unlike other CAR5s, C7CAR5's target binding site is the proximal membrane domain.
[0214] Therefore, in order to develop a better CAR structure, the inventors screened scFvs targeting the proximal CD5 membrane domain at the antigen-binding site of the proposed CAR structure using the phage display method when constructing CAR-T therapeutic agents for treating T-cell tumors.
[0215] To confirm whether the screened scFv actually binds to the proximal membrane domain of CD5, scFv protein was subjected to binding with CD5-negative K562 cell lines, K562 cell lines transduced with wild-type CD5, and K562 cell lines transduced with mutant CD5 (DXX3) that retains only the proximal membrane domain. Flow cytometry was then used to confirm whether binding occurred. Figure 11 ).
[0216] Compared with the K562 cell line and isotype control used as negative controls, multiple scFvs that bind to the K562-CD5(DXX3) cell line were identified, and three scFvs that also bind to K562-CD5(WT) were finally screened out.
[0217] The structure of the CD5 CAR used in the CD5 CAR-T therapeutic agent of the present invention is shown in [illustration]. Figure 12 .
[0218] The CD5 CAR has the following structure: a CD8-derived signaling domain; an anti-CD5 scFv sequence (VL-linker-VH domain); a c-myc-derived myc-tag domain; a CD8-derived hinge domain; a CD8-derived transmembrane domain; a 4-1BB-derived intracellular signaling domain; a CD3z-derived intracellular signaling domain; and a stop codon TAA connected in sequence.
[0219] Based on the types of anti-CD5 scFv sequences, six CAR structures are shown below. Figure 12 .
[0220] Of the six CAR structures, two CARs containing the positive control H65 scFv target the distal domain of the CD5 membrane, while four CAR structures target the proximal domain of the CD5 membrane.
[0221] To confirm the CD5 binding capacity of the screened scFvs, each CAR molecule composed of the screened scFvs was transduced into the K562 cell line, which is a CD5-negative cell line.
[0222] In K562 cell lines expressing various CAR molecules, the expression of CAR molecules was confirmed using myc-tag. Figure 13 a).
[0223] The recombinant human CD5 protein was incorporated into six cell lines and an untransduced K562 cell line, and the degree of binding was analyzed by flow cytometry. Figure 13 b).
[0224] The raw results were normalized by dividing the binding affinity to recombinant human CD5 protein by the expression level of the CAR molecule. Figure 13 c).
[0225] It was confirmed that there was no difference in the binding ability of CAR molecules of different structures to CD5 (*p<0.05, **p<0.01, ***<0.001, ns: no significance).
[0226] To confirm the CD5 binding sites of the screened scFv, the above Figure 12 The CD5 CAR molecule shown is transduced into T cells.
[0227] CD5 CAR-transduced T cells were combined with the above Figure 4 The cell line b was co-cultured at an E:T ratio of 1:1 for 48 hours, and the amount of INF-γ released into the culture medium during co-culture was determined by the cytometric bead array method.
[0228] The raw values were standardized based on the GFP expression levels of the cell lines used in each co-culture. Figure 14 ).
[0229] Using three additionally screened scFvs, C11CAR5, F8CAR5, and D9CAR5, all released INF-γ even in the presence of only the proximal domain of the CD5 membrane.
[0230] Therefore, it was confirmed that C11, F8, and D9 scFv bind to the proximal domain of the extracellular membrane.
[0231] 5. Preparation and characterization of CAR-transduced T cells targeting the proximal CD5 membrane domain
[0232] CD5 CAR-transduced T cells were prepared using the same method as described above.
[0233] NTDs without CAR gene transduction, H65CAR5 transduced with H65 CAR, A2CAR5 transduced with A2 CAR, C7CAR5 transduced with C7 CAR, C11CAR5 transduced with C11 CAR, F8CAR5 transduced with F8 CAR, and D9CAR5 transduced with D9 CAR were harvested, and the expression of CAR molecules was confirmed at each time point using myc-tag (Figure 15).
[0234] To determine the extent of cannibalism, cell viability was measured at the end of the culture. Figure 16 a).
[0235] H65CAR5 and A2CAR5 showed similar cell viability, while CAR5 targeting the proximal CD5 membrane domain showed statistically significantly higher cell viability (*p<0.05, **p<0.01, ***<0.001, ns: no significance).
[0236] In addition, the proliferation capacity of all cells was measured ( Figure 16 b).
[0237] The proliferation rate of all cells during the entire culture period was confirmed by measuring the total number of cells at the end of the entire culture, relative to the number of cells used for transduction.
[0238] H65CAR5 and A2CAR5 showed similar total cell proliferation rates, while CAR5 targeting the proximal CD5 membrane domain showed a statistically significantly higher total cell proliferation rate (*p<0.05, **p<0.01, ***<0.001, ns: no significance).
[0239] In addition, the proliferation capacity of CD5 CAR-transduced T cells was measured.
[0240] The proliferation rate of CD5 CAR-transduced T cells at 7 days of culture was confirmed by measuring the number of CD5 CAR-transduced T cells after transduction and further culture for 3 days, and the number of CD5 CAR-transduced T cells after further culture for 10 days. Figure 16 c).
[0241] H65CAR5 and A2CAR5 showed similar cell proliferation rates, while D9CAR5 showed a statistically significantly higher CD5 CAR-transduced T cell proliferation rate (*p<0.05, **p<0.01, ***<0.001, ns: no significance).
[0242] This confirms that in CD5 CAR-transduced T cells, the self-destructive level of CAR5 targeting the proximal domain of the CD5 membrane is low.
[0243] To determine the extent of cannibalism, the levels of cell surface markers and cell depletion transcription factors at the end of culture were determined.
[0244] To confirm the persistent stimulation caused by cannibalism, flow cytometry was used to confirm the cell surface expression of CD69 protein, one of the markers of cell activation. Figure 17 a).
[0245] Statistically significantly lower levels of cell activation were confirmed in C7CAR5 and D9CAR5.
[0246] Furthermore, the increased levels of immune checkpoint receptors induced by continuous stimulation were confirmed. Figure 17 b).
[0247] The PD1 immune checkpoint receptor was confirmed to be expressed at statistically significantly lower levels in C11CAR5 and D9CAR5.
[0248] The study confirmed that the LAG3 immune checkpoint receptor was expressed at a statistically significantly low level in all CAR5 receptors targeting the proximal domain of the CD5 membrane.
[0249] Furthermore, intracellular staining flow cytometry confirmed the levels of cell exhaustion transcription factors induced by continuous stimulation. Figure 17 c).
[0250] The levels of TOX transcription factor were confirmed to be statistically significantly lower in all CAR5 receptors targeting the proximal CD5 membrane domain (*p<0.05, **p<0.01, ***<0.001, ns: no significance).
[0251] This confirms that in CD5 CAR-transduced T cells, the self-destructive level of CAR5 targeting the proximal domain of the CD5 membrane is low.
[0252] 6. Analysis of the tumor cell killing ability of CAR-transduced T cells targeting the proximal CD5 membrane domain
[0253] The in vitro tumor cell killing ability was analyzed using the same method as described above. Figure 18 ).
[0254] As a result, the tumor-killing ability of CD5 CAR-transduced T cells against the Jurkat cell line, which is a CD5-positive cell line, was observed.
[0255] In addition, the in vivo tumor cell killing ability was analyzed using the same method as described above. Figure 19 ).
[0256] In vivo imaging results in small animals showed that CAR5 targeting the proximal domain of the CD5 membrane exhibited stronger tumor cell killing ability compared to CAR5 targeting the distal domain of the CD5 membrane.
[0257] This confirms that CAR5 targeting the proximal domain of the CD5 membrane has a high in vivo tumor cell killing ability in CD5 CAR-transduced T cells.
Claims
1. An antibody that specifically binds to CD5 or an antigen-binding fragment thereof, comprising: The light chain variable region includes: a light chain CDR1 having any of the amino acid sequences of sequence numbers 1, 10, 19, and 28; a light chain CDR2 having any of the amino acid sequences of sequence numbers 2, 11, 20, and 29; and a light chain CDR3 having any of the amino acid sequences of sequence numbers 3, 12, 21, and 30; and The heavy chain variable region includes: a heavy chain CDR1 having any of the amino acid sequences of sequence numbers 4, 13, 22 and 31; a heavy chain CDR2 having any of the amino acid sequences of sequence numbers 5, 14, 23 and 32; and a heavy chain CDR3 having any of the amino acid sequences of sequence numbers 6, 15, 24 and 33.
2. The antibody or antigen-binding fragment thereof according to claim 1, comprising any amino acid sequence of sequence numbers 9, 18, 27 and 36.
3. The antibody or its antigen-binding fragment according to claim 1, wherein, The antibody or its antigen-binding fragment binds to the proximal domain of the CD5 cell outer membrane.
4. The antibody or its antigen-binding fragment according to claim 3, wherein, The CD5 extracellular membrane proximal domain contains the amino acid sequence at sequence number 56.
5. The antibody or its antigen-binding fragment according to claim 1, wherein, The antibody or its antigen-binding fragment is scFv, Fab fragment, F(ab') fragment, F(ab')2 fragment or Fv fragment.
6. An anti-CD5 chimeric antigen receptor CAR, comprising: The extracellular binding domain comprises the antibody or antigen-binding fragment thereof as described in claim 1; Transmembrane domains; and Intracellular signal transduction domain.
7. The anti-CD5 chimeric antigen receptor according to claim 6, wherein, The intracellular signal transduction domain is derived from one or more of the following: CD3 zeta, FcγR, ICOS (CD278), 4-1BB (CD137), OX40 (CD134), CD27, CD28, IL-2Rβ, IL-15R-α, CD40, MyD88, DAP10, DAP12, MHC. Class I molecules, TNF receptor protein, immunoglobulin-like protein, cytokine receptor, integrin, SLAM protein, activated NK cell receptor, BTLA, Toll ligand receptor, CD2, CD7, CD30, CD40, CDS, ICAM-1, B7-H3, GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAM F7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD19, CD4, CD8α, CD8β, IL2Rγ, IL7Rα, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGA M, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, ITGB7, NKG2D, NKG2C, TNFR2, TRANCE / RANKL, DNAM1 (CD226), SLAMF4 (CD244 or 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A or Ly108), SLAM (SLAMF1 or CD150 or IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG / Cbp, CD19a and CD83 specific ligands.
8. The anti-CD5 chimeric antigen receptor according to claim 6, wherein, The transmembrane domain is derived from any one of the following T cell receptors: TCR α chain, TCR β chain, CD3ζ, CD3ε, CD28, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154, and CD278.
9. The anti-CD5 chimeric antigen receptor according to claim 6, wherein, The chimeric antigen receptor also includes a hinge domain; The extracellular binding domain is connected to the transmembrane domain via the hinge domain; and The hinge domain is derived from any one of CD8, FcγRIIIα, and IgG1.
10. The anti-CD5 chimeric antigen receptor according to claim 6, comprising any amino acid sequence from sequence numbers 51 to 54.
11. A nucleic acid molecule encoding the chimeric antigen receptor of claim 6.
12. An expression vector comprising the nucleic acid molecule of claim 11.
13. An immune cell that expresses the chimeric antigen receptor of claim 6.
14. The immune cell according to claim 13, wherein, The immune cells are selected from at least one of T cells, natural killer T cells, dendritic cells, cytotoxic dendritic cells, mast cells, natural killer cells, macrophages and their precursor cells.
15. A pharmaceutical composition for the prevention or treatment of cancer, comprising the immune cells of claim 13.
